Genomic Health Could See Japanese Sales Efforts Buoyed by Positive Oncotype DX Trial

Researchers from the Japan Breast Cancer Research Group found that Oncotype DX had "significant prognostic value" in identifying the risk of cancer recurrence in Japanese women with estrogen receptor-positive early-stage breast cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories